Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 86

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 86
---
 3 development in IBD, pending regulatory discussions. eclitasertib (SAR443122) is a small molecule targeting the receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which is being co-developed with Denali. The Phase 2 RESOLUTE study evaluating eclitasertib in patients with moderate to severe UC is ongoing. riliprubart (SAR445088) is a humanized IgG4 monoclonal antibody that binds to and inhibits C1s, thereby inhibiting classical pathway (CP) of complement activity. Activation of the CP of complement is associated with a variety of immune disorders involving the presence of autoantibodies. The asset is under clinical development in various indications (see details in “— c) Neurology” and “— b) Rare diseases” below). A Phase 2 study is currently evaluating the efficacy of riliprubart in prevention of antibody-mediated rejection (AMR) or treatment of active AMR. brivekimig (SAR442970) is a bispecific NANOBODY ® molecule that combines blockades of TNFa and of the immune co- stimulatory regulator OX40L. A Phase 2 study is assessing brivekimig in adults with moderate to severe HS; results are expected in the first half of 2025. Other assets are currently being evaluated in Phase 1 clinical studies for subsequent development in inflammatory indications: • SAR444336 , a non-beta IL2 Synthorin™ molecule designed to selectively engage CD4+ regulatory T cells (and not on effector T or NK cells). • SAR445399 , a monoclonal antibody targeting IL1R3. • SAR446422 , a bispecific antibody targeting CD28 and OX40. • SAR446959 , a NANOBODY ® molecule targeting Matrix Metallopeptidase 13 (MMP13), A Disintegrin And Metalloproteinase with Thrombospondin Motifs 5 (ADAMTS5) and a cartilage anchoring protein (CAP).

| 36 | SANOFIFORM 20-F2024 |

| PART I                             |
| ITEM 4. Information on the Company |

b) Rare Diseases fitusiran (SAR439774) is a first-in-class, subcutaneously administered antithrombin siRNA therapy. The FDA granted fitusiran breakthrough therapy and fast-track designations for hemophilia A/B. Fitusiran also obtained orphan